Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.
Can personalized ctDNA finally solve the risk stratification gap in therapy-resistant early breast cancer?
New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor […]